Diabetic retinopathy

February 10, 2018

Molecular therapy for Diabetic retinopathy: D-3 Hydroxybutyrate (D3HB) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 11/February/2017, 12.33 pm

Molecular therapy for Diabetic retinopathy: D-3 Hydroxybutyrate (D3HB) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 11/February/2017, 12.33 pm https://genomediscovery.org/wp-content/uploads/2018/02/D3HBEM-inhibits-EPHX2-1.jpg2_-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/D3HBEM-inhibits-EPHX2-1.jpg2_-1.jpg February 10, 2018 February 10, 2018

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

February 4, 2018

Hormonal therapy for Diabetic nephropathy (DN): Triiodothyronine (T3), a thyroid hormone, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 4/February/2018, 10.18 pm

Hormonal therapy for Diabetic nephropathy (DN): Triiodothyronine (T3), a thyroid hormone, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 4/February/2018, 10.18 pm https://genomediscovery.org/wp-content/uploads/2018/02/Triiodothyronine-promotes-insulin-sensitivity-and-weight-loss-and-protects-against-obesity-TIIDM-through-up-regulation-of-PKM2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/Triiodothyronine-promotes-insulin-sensitivity-and-weight-loss-and-protects-against-obesity-TIIDM-through-up-regulation-of-PKM2.jpg February 4, 2018 February 4, 2018

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

February 2, 2018

Hormonal therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Triidothyronine (T3), Epicatechin and Matrine (T3EM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/February/2018, 12.42 am

Hormonal therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Triidothyronine (T3), Epicatechin and Matrine (T3EM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 3/February/2018, 12.42 am https://genomediscovery.org/wp-content/uploads/2018/02/T3EM-attenuates-diabetic-retinopathy.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/T3EM-attenuates-diabetic-retinopathy.jpg2_.jpg February 2, 2018 February 2, 2018

February 1, 2018

Molecular hydrogen-based therapy for Diabetic retinopathy: H2-rich water inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 2/February/2018, 12.30 am

Molecular hydrogen-based therapy for Diabetic retinopathy: H2-rich water inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 2/February/2018, 12.30 am https://genomediscovery.org/wp-content/uploads/2018/02/Epicatechin-and-Matrine-dissolved-in-H2-rich-water-inhibits-EPHX2.jpg2_.jpg3_.jpg4_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/Epicatechin-and-Matrine-dissolved-in-H2-rich-water-inhibits-EPHX2.jpg2_.jpg3_.jpg4_.jpg February 1, 2018 February 2, 2018

February 1, 2018

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Pyridoxamine and Saxagliptin (PAS) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 2/February/2018, 12.04 am

Molecular therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Pyridoxamine and Saxagliptin (PAS) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 2/February/2018, 12.04 am https://genomediscovery.org/wp-content/uploads/2018/02/Pyridoxamine-and-Saxagliptin-PAS-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/Pyridoxamine-and-Saxagliptin-PAS-inhibits-DNMT3a-expression-induces-FGF21-expression-promotes-regeneration1.jpg February 1, 2018 February 1, 2018

January 24, 2018

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Lansoprazole, Epicatechin and Matrine (LPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 25/January/2018, 12.41 am

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Lansoprazole, Epicatechin and Matrine (LPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 25/January/2018, 12.41 am https://genomediscovery.org/wp-content/uploads/2018/01/LPEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-promotes-pericite-viability-inhibits-vascular-permeability.jpg4_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/LPEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-promotes-pericite-viability-inhibits-vascular-permeability.jpg4_.jpg January 24, 2018 January 24, 2018

Popular Post